Schoenberg Mark 4

What Happened Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 10,000 shares on July 9, 2026. The reported weighted-average price was $40.00, generating gross proceeds of approximately $400,000. The shares were sold in multiple executions at prices between $40.00 and $40.02. This transaction is coded as a sale (S) and was executed pursuant to a Rule 10b5-1(c) trading plan.

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-10 (timely filing).
• Shares sold: 10,000; weighted-average price: $40.00; proceeds ≈ $400,000.
• Reported price range: $40.00–$40.02 (multiple transactions; weighted avg shown).
• Footnote: Sale made under a Rule 10b5-1(c) plan adopted August 15, 2025; this sale is the final sale under that plan (F1).
• Footnote: The reporting person will provide breakdown of the number of shares at each price on request (F2).
• Shares owned after the transaction: not specified in the provided filing.

Context The sale was executed under a pre-established Rule 10b5-1 trading plan, which typically indicates the trades were planned in advance rather than market-timed. Sales under such plans are often routine and do not necessarily signal a change in an insider’s view of the company. Retail investors should consider this alongside other company and market information before drawing conclusions.